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Abstract Human pluripotent stem cells [PSCs; including
human embryonic stem cells (ESCs) and induced pluripotent
stem cells (iPSCs)] can infinitely proliferate in vitro and are
easily accessible for gene manipulation. Megakaryocytes
(MKs) and platelets can be created from human ESCs and
iPSCs in vitro and represent a potential source of blood cells
for transfusion and a promising tool for studying the human
thrombopoiesis. Moreover, disease-specific iPSCs are a
powerful tool for elucidating the pathogenesis of hemato-
logical diseases and for drug screening. In that context, we
and other groups have developed in vitro MK and platelet
differentiation systems from human pluripotent stem cells
(PSCs). Combining this co-culture system with a drug-
inducible gene expression system enabled us to clarify the
novel role played by c-MYC during human thrombopoiesis.
In the next decade, technical advances (e.g., high-throughput
genomic sequencing) will likely enable the identification of
numerous gene mutations associated with abnormal throm-
bopoiesis. Combined with such technology, an in vitro
system for differentiating human PSCs into MKs and
platelets could provide a novel platform for studying human
gene function associated with thrombopoiesis.
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Introduction
Platelets are essential for hemostasis and thrombosis. They
also play vital roles in wound repair, inflammation, neoan-
giogenesis, and tumor metastasis. In humans, approximately
1 9 1011 platelets are produced each day, presumably
through the cytoplasmic fragmentation of megakaryocytes
(MKs), their precursor cells, and production can be signifi-
cantly increased on demand [1]. MK and platelet numbers
are thought to be primarily controlled by thrombopoietin
(TPO), whose serum levels may be regulated in part through
a process entailing its binding to TPO/c-MPL (the throm-
bopoietin receptor) on platelets and MKs and its subsequent
internalization and degradation (sponge theory) [2, 3].
Platelet production requires the commitment of hema-
topoietic stem cells (HSCs) to the MK lineage, followed by
proliferation of the progenitors and terminal differentiation.
During maturation, the MK precursor loses its capacity to
divide but increases its ploidy through a process called
endomitosis or endoreduplication, and also develops a
unique membrane complex called the demarcation mem-
brane system, as well as various types of granules,
including lysosomes, dense granules, and a-granules. Fully
mature MKs form an extensive internal demarcation
membrane, which is continuous with the plasma membrane
and serves primarily as a membrane reservoir for the for-
mation of the precursors of cytoplasmic extensions called
proplatelets [4, 5]. These sequential processes are con-
trolled through the orchestrated activities of numerous
signaling molecules, microRNAs, transcriptional factors,
and their downstream target genes. Various gene-targeted
mouse models have contributed to the characterization of
the linkage between the machinery of MK maturation and
platelet release, and the roles played by the transcriptional
factors involved [6–11].
N. Takayama  K. Eto (&)
Clinical Application Department,
Center for iPS Cell Research and Application,
Kyoto University, 53 Kawahara-cho,




Cell. Mol. Life Sci. (2012) 69:3419–3428
DOI 10.1007/s00018-012-0995-4 Cellular and Molecular Life Sciences
123
It has become evident, however, that some human
diseases are not fully recapitulated in genetically engi-
neered mouse models. In that regard, several groups,
including ours, have developed in vitro MK and platelet
differentiation systems from human pluripotent stem cells
(PSCs) [12–17]. Human PSCs, which are easily accessible
for controlled and specific genetic manipulation, are a
promising tool for studying transcriptional regulation
within the defined constraints of human MK development
or cell signaling within platelets, which are anucleate and
thus not amenable to direct gene manipulation. Moreover,
patient-specific-induced pluripotent stem cells (iPSCs)
enable one to investigate the pathogenesis of disease or
test drugs using in vitro estimation assays based upon
specific cell-traced differentiation, without the need for
human subjects. This review focuses on the study of
human thrombopoiesis using in vitro differentiation sys-
tems for human PSCs.
The study of human thrombopoiesis in vitro
Sources of MKs and platelets
The rarity of MKs within bone marrow limits the use of
bone marrow specimens for studies of megakaryopoiesis
and platelet generation. For this reason, human thrombo-
poiesis has largely been studied using in vitro
differentiation systems developed from human primary
hematopoietic stem/progenitor cells derived from cord
blood, bone marrow, and mobilized peripheral blood-
derived CD34? cells [18–21]. These systems have enabled
each developmental step in the process of megakaryopoi-
esis to be resolved and examined, and have also
contributed to our understanding of human platelet bio-
genesis. However, primary human hematopoietic cells are
heterogeneous, reflecting the differences in their genetic
backgrounds, which can lead to a lack of consistency in the
results. Moreover, while platelets are not amenable to
genetic manipulation, it is possible to manipulate MKs to
investigate the molecules expressed in platelets, but the
efficiency of genetic transduction in MKs and their pro-
genitors is not high.
On the other hand, we previously showed the utility of
an in vitro MK differentiation system derived from
genetically manipulated mouse ESCs [22], which can be
easily expanded and provides relatively homogeneous
cells. This strategy also seemed applicable to the study of
human thrombopoiesis using human PSCs, prompting us to
establish an in vitro differentiation system with human
PSCs that enables genetic manipulation for investigating
human thrombopoiesis.
In vitro generation of MKs and platelets from human
PSCs
The culture methods needed to maintain the pluripotency of
mouse ESCs are now well established and were improved by
the finding that administration of two inhibitor (2i) reagents
(MAP kinase inhibitor and GSK3b inhibitor) stabilizes the
ground state/naive state [23]. In addition, differentiation
protocols are being developed for application to a variety of
cells and tissues, and several groups have reported producing
platelets and/or MKs in vitro [22, 24, 25]. The first report of
MK generation from human ESCs was presented by Gaur
et al. [26]. They differentiated human ESCs on OP9 cells, a
bone marrow stromal cell line derived from mice lacking
macrophage colony stimulating factor [27]. OP9 cells are
useful feeder cells and support differentiation of both mouse
and human ESCs into mature hematopoietic cells in vitro.
Gaur’s group observed that after 15–17 days of co-culture in
the presence of TPO, ESC-derived MKs began to express
specific surface antigens, including two lineage markers,
cluster of differentiation (CD) 41a (CD41a; integrin aIIb)
and CD42b (GPIba), but no platelets were detected in this
system [26]. We also failed to generate large numbers of
platelet-like particles from human ESCs by this basic
protocol.
By testing various combinations of feeder cells, cyto-
kines, and culture periods, we were able to develop a novel
in vitro differentiation system in which platelet-generating
MKs were generated from human ESCs [12]. When we co-
cultured human ESCs with 10T1/2 cells, a highly stable
fetal mesenchymal cell line derived from a C3H mouse
strain [28], in the presence of vascular endothelial growth
factor (VEGF), unique sac-like structures derived from the
ESCs (ES-sacs) appeared on day 14 of culture.
While it is well known that conventional ESC differ-
entiation protocol with feeder cells by Gaur et al. [26]
require the reseeding procedures both on day 7 and 11
(Fig. 1a), there was no necessity of reseeding procedure for
up to 14 days on the appearance of ES-sac structure in our
protocol (Fig. 1b).
These ES-sacs, particularly their external layer, expressed
several endothelial markers, including CD31, CD34, and
VEGF-receptor 2. ES-sac also contained CD34?/CD43?/
CD45? hematopoietic progenitors inside that exhibited
hematopoietic colony-forming potential in semisolid culture
and differentiated into a variety of mature cells, i.e., not only
MKs capable of releasing platelets, but also erythrocytes,
lymphocytes, macrophages, and granulocytes, under condi-
tions towards specific lineage commitment.
On the other hand, hESC-derived colonies that did not
form ES-sacs failed to differentiate into hematopoietic
cells, indicating that the ES-sac concentrated multipotent
hematopoietic progenitors inside.
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Early hematopoietic cells reportedly originate from he-
mangioblasts [29], which are a common precursor of both
vascular endothelial cells and hematopoietic cells. ES-sacs
may mimic the early hematopoietic organ, within which
hematopoiesis and vasculogenesis occur simultaneously,
and may also contain hematopoietic niche circumstances
Fig. 1 Schematic diagrams of culture systems generating megak-
aryocyte and platelet from human pluripotent stem cells.
a Conventional method (multi-round replating); hESCs are differen-
tiated on OP9 stromal cells. On days 7 and 11, single cells derived
from differentiated human ESC colonies are transferred onto fresh
OP9 cells and further cultivated up to 17 days. In this culture system,
platelets were hardly produced as reported. b ES/iPS-sac method;
hESCs are co-cultured with 10T1/2 or OP9 stromal cells. On day 14
of culture, ESC/iPSC-derived sacs (ES/iPS-sac) are collected by using
cell scraper and filtered with cell strainer to concentrate hematopoietic
progenitors. The hematopoietic progenitors are then transferred onto
fresh 10T1/2 or OP9 stromal cells and cultivated up to day 26.
Megakaryocytes can be matured for producing platelets efficiently in
this protocol. c Hemangioblast/Blast colony (BC) method; hESCs are
transferred to ultra-low attached culture dishes in serum-free condi-
tion with cytokine combination (*1) for *4 days leading to embryoid
body (EB) formation. Single cells derived from EBs are again
transferred to ultra-low attached culture dishes in serum-free condi-
tion with cytokine combination (*2) and 1% methylcellulose for
2–4 days towards promotion of blast colonies (BCs). BCs are
differentiated to MK lineage cells in the presence of SCF, TPO, IL-
11 for 4–6 days. These steps are all feeder-free conditions. Platelet-
generation stage requires OP9 stromal cells as evidenced by efficient
yield of platelets but not without OP9 stromal cells. (*1) BMP4,
VEGF, SCF, TPO, and FLT3L, (*2) BMP4, VEGF, SCF, TPO, EPO,
FLT3L, G-CSF, GM-CSF, and IL-6
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for hematopoietic stem cells (HSCs) and/or hematopoietic
progenitor cells (HPCs).
Co-culture for an additional 7–11 days in the presence
of 100 ng/ml TPO, 50 ng/ml stem cell factor (SCF) and
25 U/ml heparin promotes differentiation of the hemato-
poietic progenitors within the ES-sacs into MKs [12, 13].
Of the cells, 50–60 % consistently express CD41a, CD42a,
and CD42b, which are essential and specific cell-surface
molecules expressed on MKs and platelets [30, 31]. During
MK maturation, a broad range of internal membrane sys-
tems, granules, and organelles are assembled [32–34], and
the mature MKs contain an extensive internal demarcation
membrane that serves as a membrane reservoir for later
formation of proplatelets. In addition, an open canalicular
system (OCS) for granule release is formed prior to the
initiation of proplatelet assembly, so that when platelets are
stimulated, the granules are released via the OCS [35]. We
found a large number of proplatelet-forming MKs from day
22 to day 26 of culture, suggesting a successful develop-
ment of demarcation membrane system (DMS) for platelet
release and yield.
We also confirmed that various types of human iPSCs
can be differentiated into mature MKs that release platelets
in vitro [13], and we are presently confident that the ES/
iPS-sac method is a consistent and stable system for cre-
ating hematopoietic cells in vitro.
To establish xeno-free platelet generation system, Lu
et al. have recently developed a unique feeder- and animal
serum-free culture system in which ‘hemangioblast’ can be
efficiently induced into hematopoietic progenitors [36],
which in turn create erythrocytes [37], MKs, and platelets
[15]. On the other hand, in such a system, adequate platelet
production (yield) still must require known feeder cells
OP9 mouse stromal cells, indicating that platelet release
should be dependent upon feeder cells per se and/or critical
factor(s) from feeder cells (Fig. 1c).
Development and maturation of MKs derived
from human PSCs
The use of human HSCs has enabled the process of MK
development to be characterized in detail [33]. The most
primitive MK progenitors are the highly proliferative
potential-colony-forming unit-MKs (HPP-CFU-MKs) and
the burst-forming unit-MKs (BFU-MKs). BFU-MKs are
capable of producing a more differentiated MK progenitor,
the colony-forming unit-MK (CFU-MK), which can then
differentiate into mature MKs that increase in size and ploidy
through endomitosis. The maturation of MKs from HSCs is
associated with changes in the expression of CD antigens,
whereas MK progenitors (HPP-CFU-MK, BFU-MK, and
CFU-MK) and immature MKs express CD34 [38], more
mature MKs are negative for CD34 expression. The most
widely used markers for examining MK differentiation are
CD41a/CD61 and CD42 (GPIb/IX/V complex; the vWF
receptor). CFU-MKs are the first MK lineage to have been
identified based on a distinct surface phenotype that
expresses CD41a/CD61 antigen. CD42 is expressed slightly
later than CD41a/CD61 [38]; however, the expression of
both correlate with MK maturity. Thus, during megakaryo-
poiesis from human HSCs, the CD34?CD41a?CD42? and
CD34-CD41a?CD42? phenotypes represent more mature
MKs, while CD34?CD41a?CD42- cells are intermediate,
not fully mature, MKs.
To clarify the relationship between the development of
MKs derived from human PSCs and the changes in CD
antigens, we isolated and divided hematopoietic progeni-
tors from ES-sacs into CD34?/CD41a-, CD34?/
CD41a?, CD34–/CD41a?, and CD34-/CD41a- sub-
populations, and then allowed them to differentiate into
MKs on 10T1/2 feeder cells or used RT-PCR to assess their
gene expression. Most CD34?/CD41a? and CD34-/
CD41a? cells should be differentiated into CD41a?/
CD42b (GPIba)? mature MKs, indicating both populations
were committed to MK lineage.
On the other hand, 40 % of hematopoietic cells derived
from the CD34?/CD41a- population were MKs. This pop-
ulation generated multi-lineage myeloid colonies, such as
erythrocyte, MKs, macrophage, or granulocytes, in colony-
forming assay, indicating that the CD34?/CD41a- popula-
tion contains the potential for differentiation into both
megakaryocytic and other lineages. Using RT-PCR, we con-
firmed that CD34?/CD41a- progenitors can develop into
CD41a? populations. In addition, the CD34?/CD41a? cells,
but not CD34?/CD41a- cells, also expressed GATA-1,
FOG-1, Fli-1, and NF-E2, which are required for megak-
aryopoiesis [39]. These findings are consistent with the
developmental behavior observed during megakaryopoiesis
from HSCs within bone marrow or cord blood [40, 41].
Characterization of human ESC/iPSC-derived platelets
in vitro
When we examined the surface markers of human ESC/iPSC-
derived platelet-like particles using flow cytometry with the
same forward- and side-scatter gates suitable for fresh adult
human platelets, we found that the culture supernatants con-
tained CD41a? particles, which also expressed other
functional receptors normally found on platelets, including
CD42a (GPIX), CD42b (GPIba), and GPVI. About half of the
CD41a? platelets generated in vitro lost CD42b (GPIba) due
to cleavage of its extracellular N-terminal region by a disin-
tegrin and metalloproteinase (ADAM) 17 (also referred to as
tumor necrosis factor a converting enzyme, TACE) [42],
though GPIba could be restored by addition of a metallopro-
teinase inhibitor to the culture [13].
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Electron microscopic examination of the cytosolic
structures of human ESC/iPSC-derived platelets revealed
their morphology to be similar to that of human peripheral
blood-derived platelets, with normal microtubules, gran-
ules, and OCS. These platelets also displayed integrin
aIIbb3 (CD41a/CD61 complex) activation, which is
essential for platelet aggregation, and they spread in
response to the physiological agonists ADP or thrombin.
Human ESC/iPSC-derived platelets thus appear structur-
ally and functionally intact in vitro, but the most important
function of platelets in vivo is hemostasis and thrombus
formation under flow conditions. Earlier in vivo imaging
was capable of detecting only mass platelet aggregation
[43]. However, to visualize the behavior of individual
platelets upon initiation of adhesion to an injured vessel
wall and the subsequent steps in thrombus formation under
flow conditions within vessels, we recently developed a
novel in vivo imaging system that employs high-spatio-
temporal resolution confocal laser microscopy [44, 45].
With our system, intravenous administration of hemato-
porphyrin followed by laser exposure induces rapid
formation of a microthrombus. In these experiments, iPSC-
platelets stained with tetramethylrhodamine ethyl ester, a
membrane-permeant, cationic, red-orange fluorescent dye
that is readily sequestered by active mitochondria, were
transfused into a NOG (NOD/Shi-scid, IL-2Rcnull) mouse
with thrombocytopenia, where red staining then indicated
living iPSC-platelets. Following laser-induced vessel
injury, we clearly observed that iPSC-platelets initially
adhered to the injured vessel wall, coordinating with host
platelets, and that this process ultimately led to thrombus
formation and vessel occlusion, which suggests the iPSC-
derived platelets are functionally intact in vivo [13]. Sim-
ilarly, using a conventional imaging system that enabled
them to detect mass aggregations, Lu et al. [15] observed
that human ESC-derived platelets contributed to thrombus
formation in living mice. Collectively then, these findings
indicate that platelets generated from human PSCs in vitro
share many, if not all, of the characteristics of human
peripheral blood-derived platelets. Using human iPSC
specimens, we also confirmed that human iPSCs created
from dermal fibroblasts through artificial reprogramming
could be differentiated in vitro into functional platelets that
could serve to supply HLA-identical platelets, or perhaps
the use of disease-specific iPSCs could provide new
information able to serve as a platform for the study of
abnormal thrombopoiesis.
In vitro analysis of the genes for platelet biogenesis
using PSCs with gene manipulation
Megakaryopoiesis is a complex process governed by the
orchestrated activities of numerous molecular mediators,
especially transcriptional factors, signaling molecules,
microRNAs, and the products of their various target genes.
Several gene-targeted mouse models have provided
important information about thrombopoiesis, but the gen-
eration of gene-targeted mice is both time-consuming and
expensive; moreover, it is sometimes embryonically lethal
before the onset of hematopoiesis, which makes it difficult
to analyze the MK lineage. In that context, several groups,
including ours, previously showed the advantages of in
vitro differentiation of MKs from mouse ESCs over gene-
targeted mouse models for analysis of functional molecules
in MKs and platelets [22, 46–48].
The Wiskott-Aldrich syndrome protein (WASp) homo-
log Wave (WASp family Verprolin-homologous protein)
functions downstream of Rac, a member of the Rho family
of small GTPases, and plays a pivotal role in lamellipodia
formation in cells. Wave2-null mice die by embryonic day
11.5 or 12.5 due to a defect in vascular development. We
therefore generated Wave2-/- mouse ESCs from which
we then derived MKs using our in vitro differentiation
culture system. The Wave2-/- MKs generated in this way
showed severely impaired terminal differentiation, platelet
production, and agonist-induced peripheral lamellipodia
formation on fibrinogen. We also confirmed that using
small interfering RNA (siRNA) to knock down Abl-inter-
actor (Abi)1, which forms a complex with Wave2,
produces a phenotype that is striking similar to Wave2-/-
MKs; that is, both their maturation and integrin aIIbb3-
mediated spreading were impaired. This is indicative of the
indispensable role played by the Wave2/Abi1 complex in
MK maturation and lamellipodia formation [46, 49].
It is known that the genetic mutations in some mouse
models fully recapitulate the phenotype of the corresponding
human disease. This is not always the case, however. In fact,
mutation or deletion of several genes (e.g., NFE2, Wave2, and
Spectrin) known to be important for thrombopoiesis in mouse
models, have not been identified in patients with thrombocy-
topenia [8, 46, 50]. Consequently, we are unable to validate the
function of these genes in human cells. Fortunately, recent
developments with human ESCs [51] and iPSCs [52–54] and
with gene-targeting technology enable us to provide an alter-
native tool for the study of human hematopoietic ontology and
lineage commitment. For example, we used gene manipula-
tion with human iPSCs to characterize the role played by c-
MYC in human megakaryopoiesis. It had already been repor-
ted that c-Myc plays an essential role in both embryonic and
adult hematopoiesis, though its effects on megakaryopoiesis
and thrombopoiesis in various mouse models remained
unclear [55–58]. Two studies of the effects of inducible c-Myc
overexpression on the control of MK-specific differentiation
showed that c-Myc exerts a positive effect on the proliferation
of MK progenitors [55, 56]. Moreover, c-Myc is reportedly
essential for the TPO-c-mpl axis in megakaryopoiesis [57]. On
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the other hand, more recent studies using c-Myc-deficient mice
showed that the absence of the gene actually leads to a cell-
autonomous increase in the number of low-ploidy MKs and
platelets [58]. The reasons for this apparent discrepancy are
still not completely clear. However, by comparing the effi-
ciency of MK and platelet generation from several iPS clones
established using retroviral vectors harboring either four
(OCT3/4, SOX2, KLF4 and c-MYC) or three (without c-MYC)
reprogramming factors, we demonstrated that although c-
MYC is beneficial for MK proliferation, its sustained expres-
sion inhibits platelet release. This idea was confirmed by
additional experiments showing that overexpression of c-
MYC, but none of the other reprogramming factors (OCT3/4,
SOX2, KLF4), recapitulated the time course of the enhanced
megakaryopoiesis. In addition, flow cytometry revealed that
most of the cells in specimens overexpressing c-MYC were
CD41a?GPIba?, but cells in the other specimens were not,
though only mononuclear and lower-ploidy cells were present.
The numbers of platelets per MK, one indicator of MK mat-
uration, were quite low in specimens overexpressing c-MYC,
and the released platelet-like particles did not express GPIba,
suggesting that MKs from specimens overexpressing c-MYC
were immature. Interestingly, the phenotype of platelets gen-
erated from MKs overexpressing c-MYC was similar to that in
Gata1-/- mouse models, which showed low expression of
GPIba, abnormal ultrastructure, and defective integrin aIIbb3
activation in response to thrombin or ADP [59].
The results summarized above led to us to conclude that
excessive and sustained expression of c-MYC in human
ESCs may promote lineage commitment into megakaryo-
poiesis without maturation. Moreover, overexpression of c-
MYC in hematopoietic cells to levels that are inhibitory for
platelet generation activates expression of the senescence/
apoptosis-inducing p14 (ARF) and p16 (INK4A) genes,
leading to senescence and apoptosis without maturation
(Fig. 2). Thus, there appears to be a narrow window of c-
MYC expression for efficient platelet development.
To further confirm whether an increase and subsequent
decline in c-MYC is critical for megakaryopoiesis leading
to an efficient platelet yield, we prepared a Sendai viral
vector (SeV) harboring the four reprogramming genes; this
enabled RNA viral transduction during the generation of
human iPSCs without integration of DNA into the chro-
mosome [60]. Thereafter, a doxycycline (DOX)-inducible
c-MYC overexpression system in a lentiviral vector was
applied to the SeV-based human iPSCs. This approach
enabled us to confirm that transient up-regulation of c-MYC
expression at the level of the MK progenitors and its
subsequent decline increased the total numbers of mature
MKs, proplatelets and GPIba? platelets [13].
Studying thrombopoiesis using patient-specific iPSCs
Our culture system enables us to investigate in detail the
developmental stages of MKs and platelets derived from
human iPSCs. Moreover, MKs derived from disease-spe-
cific human iPSCs represent a powerful tool for
investigating the unresolved aspects of the mechanisms
underlying thrombocytopenia and for screening novel
therapeutic agents for patients suffering from reduced
platelet production and/or their impaired function (Fig. 3).
This is illustrated in the following example. Congenital
amegakaryocytic thrombocytopenia (CAMT) is an auto-
somal recessive disorder caused by the loss of function of
c-MPL, the gene encoding the TPO receptor. It presents at
birth with severe thrombocytopenia and evolves into fatal
bone marrow failure in the early years of life [61]. A c-
Mpl-/- mouse model failed to fully recapitulate the dis-
ease phenotype; c-Mpl-/- mice showed sustained
thrombocytopenia and reduced numbers of marrow cells
Fig. 2 Proposed model of
thrombopoiesis by c-MYC. We
observed at least two distinct
patterns of megakaryopoiesis in
association with c-MYC
kinetics. One is that excessive
and sustained expression of c-
MYC in MKs induces INK4A
and ARF, leading to senescence
and apoptosis without
maturation of MKs. Another is
that a decline in the c-MYC
expression after a transient
increase is a hallmark for MKs
that production of functional
GPIba? platelets is apparently
detectable
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throughout their lives, but they survived to old age without
developing bone marrow failure. To clarify the differential
phenotype caused by the loss of MPL between humans and
mice, we established iPSCs derived from skin fibroblasts
collected from a CAMT patient treated with curative bone
marrow transplantation. We then used our in vitro culture
system to obtain hematopoietic progenitors to evaluate the
function of MPL during the early and late phases of human
hematopoiesis [62]. This patient’s iPSCs provided valuable
insight into the mechanism of CAMT development.
Application of human PSC-derived platelets for future
transfusion medicine
Proof of concept: the stable supply of HLA-identical
platelet concentrates
It is well known that repeated transfusion induces pro-
duction of antibodies against allogenic HLA on the
transfused platelets [63], which renders the patient unre-
sponsive to platelet transfusion therapy. To avoid such
immune reactions following multiple allogeneic platelet
transfusions, it is desirable to use HLA-matched or autol-
ogous platelets. In this context, we propose that the use of
HLA-matched human iPSCs may be an effective strategy
for generating functional platelets for patients requiring
repeated transfusion. We have shown that iPSC-derived
platelets are functional in vivo and could represent a novel
solution for the shortage of donated platelets [13]. Now we
attempt to modify the culture system to provide huge
amount of platelets for clinical application.
Preservation of platelet function in vitro using
metalloproteinase inhibitor
The functional platelet paradigm in hemostasis and
thrombosis is the initiation of platelet adhesion to the
extracellular matrix [64]. Key events in that process are the
interaction between GPIba and vWF present in the extra-
cellular matrix [64], as well as the simultaneous interaction
between surface-bound collagen and the platelet receptors
GPVI and integrin a2b1 [65]. The net result is activation of
integrin aIIbb3, which turns into a competent fibrinogen
receptor and leads to the formation of platelet aggregates
[64]. Notably, aged platelets show a tendency to shed GPV
and the extracellular domain of GPIba, which contains the
binding sites for vWF and thrombin [66, 67]. This phe-
nomenon makes it difficult to preserve platelet concentrates
for more than 7 days.
The shedding process likely involves the action of
ADAM 17 and leads to a reduction in platelet function [42,
68]. We observed that, in culture, mouse ESC-derived
platelets shed the extracellular domains of GPIba and GPV,
as well as GPVI, possibly through the action of ADAM10,
which reduces aIIbb3 activation and actin polymerization
and impairs thrombus formation. However, administration
of the metalloproteinase inhibitor GM6001 during differ-
entiation increased the expression of GPIba and GPVI and
improved both thrombogenesis in vitro and post-transfu-
sion recovery in vivo [25]. Administration of GM6001 also
inhibited shedding of the extracellular domain of GPIba
from human iPSC-derived platelets [13]. These data sug-
gest that regulation of metalloproteinases in culture could
Fig. 3 Disease modeling of
thrombopoiesis using patient-
specific iPSCs. iPS cell
technology enables us to model
human disease in vitro. Disease-
specific iPSCs can be
established from somatic cells
in an individual patient by
introduction of the defined
reprogramming factors.
Combing with in vitro
differentiation system, genetic
and epigenetic studies would




drug screening for platelet
disorders will also be applicable
by using this system
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be useful for obtaining high-quality and efficacious human
iPSC-derived platelets for transfusion.
Conclusions and future directions
Several gene-targeted mouse models have provided impor-
tant information about thrombopoiesis. While the genetic
interventions, i.e., mutations by mouse models recapitulate
the phenotype of the corresponding human disease, some of
the models fail to show the mirror of human diseases. Of note
from recent important work is that there is the difference of
ortholog-matched mRNA expression between mouse and
human platelets by using RNA sequence technology. This
study showed that 4,990 mRNAs were commonly expressed
both in human and mouse platelets, but 3,592 mRNAs were
specific for human platelets and 1,022 mRNAs were specific
for mouse platelets. They are associated with previously
described functional disparities between mouse and human
platelets at the transcript level, including protease activated
receptor-1 (PAR1) [36, 69], protease activated receptor-3
(PAR3) [70], and platelet activating factor receptor (PAF-R)
[71]. These strongly indicate the value of the study regarding
human thrombopoiesis by human hematopoietic cells. In
general, human primary hematopoietic stem/progenitor cells
derived from cord blood, bone marrow, or peripheral blood
are a main resource. We herein propose human PSCs as an
alternative source.
MKs generated from human PSCs in vitro have the
potential to form proplatelets that function like those
derived from human HSCs, and the platelets released are
functionally comparable to human peripheral blood-
derived platelets. The in vitro generation of MKs and
platelets from human PSCs has four advantages over pri-
mary HSCs. First, human PSCs are pluripotent cells that
can proliferate almost indefinitely in vitro, thereby stably
providing experimental samples that yield reproducible
results. By contrast, inescapable variation in genetic
background for each experiment makes it difficult to obtain
consistent results with primary HSCs derived from cord
blood or bone marrow. Second, human PSCs are a prom-
ising cell source for studying the ontogeny of blood cells in
defined steps. It has been well demonstrated in mouse
models that HSCs can provide all types of blood cells
throughout life. Blood cells arise at the yolk-sac and transit
to the AGM, fetal liver, and bone marrow during ontogeny
[72–74]. In humans, however, the development of hema-
topoietic cells has not been characterized because of the
difficulty in obtaining samples from human embryos.
Human PSCs are an effective tool that enables one to
recapitulate human ontology in vitro by appropriately
defining the culture conditions, as we have shown. Third,
human PSCs are easily amenable to gene manipulation.
Megakaryopoiesis is a complex process governed by the
orchestrated activities of numerous molecular mediators,
especially transcriptional factors, signaling molecules,
microRNAs, and the products of their various target genes.
Many transcriptional factors including Ets1, Runx1, Scl/
tal1, Gata1, NFE2, Mef2C, MafG, and MafK are involved
in megakaryopoiesis [75–77].
Megakaryopoiesis is also controlled by a lot of mi-
croRNAs by regulating the expression of these target genes
[71]. To study the unknown role of transcriptional factors
or microRNAs on human thrombopoiesis, human PSCs
should be a useful tool. For example, we were able to
demonstrate the novel function of c-MYC on human
thrombopoiesis by using in vitro differentiation of human
PSCs with gene manipulation.
Fourth, patient-specific iPSCs facilitate the study of
disease mechanisms and drug screening [78]. Although
gene-targeted mouse models have provided important
information on the pathogenesis of human disease, some
human diseases are not completely recapitulated in these
models. For example, to clarify the function of c-MPL, the
TPO receptor, we established iPSCs from skin fibroblasts
collected from a patient with CAMT. In vitro differentia-
tion of CAMT-iPSCs revealed the critical role played by c-
MPL during early human thrombopoiesis. We anticipate
that future technical advances in genome sequencing and/
or epigenome analysis will enable identification of
numerous gene mutations associated with congenital
thrombocytopenia or megakaryocytic leukemia. When that
happens, disease-specific iPSCs would be a powerful tool
for distinguishing pathogenic gene mutations from the
many neutral mutations. Finally, establishment of an in
vitro system for platelet generation from human iPSCs
could usher in a new era of platelet transfusion therapy.
Platelets generated from human iPSCs in vitro show nor-
mal function during thrombus formation in living mice
[13], but a more efficient system for platelet generation will
be required for future clinical applications.
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